miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcoma.


Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
01 05 2020
Historique:
received: 09 09 2019
revised: 16 01 2020
accepted: 27 02 2020
pubmed: 7 3 2020
medline: 31 12 2020
entrez: 7 3 2020
Statut: ppublish

Résumé

The prognosis of patients with metastatic rhabdomyosarcoma (RMS), the most common type of soft tissue sarcoma in children, is poor and no strategies have been identified to improve their dismal prognosis. Alpha-9 integrin (ITGA9) plays a particularly crucial role in cancer progression and invasiveness. Despite the consensus on the remarkable pro-oncogenic potential of this protein, the miRNA-mediated regulation of ITGA9 has barely been studied to date. In the present study, miR-7 and miR-324-5p were selected as the best candidates after a screening to find ITGA9 regulators, and their effects on cell proliferation and invasion in RMS are described and characterized for the first time. Interestingly, the overexpression of both miRNA produced a clear impairment of cell proliferation, while miR-7 also induced a remarkable drop in cell invasion. Furthermore, the stable overexpression of both miRNA was found to reduce tumor growth in orthotopic RMS models and miR-7 was able to impair metastatic lung colonization. Consequently, we conclude that miR-7 and miR-324-5p show anti-oncogenic and anti-metastatic potential, thereby opening up the possibility of being used as novel therapeutic tools to avoid RMS progression.

Identifiants

pubmed: 32142919
pii: S0304-3835(20)30104-X
doi: 10.1016/j.canlet.2020.02.035
pii:
doi:

Substances chimiques

ITGA9 protein, human 0
Integrins 0
MIRN324 microRNA, human 0
MIRN7 microRNA, human 0
MicroRNAs 0
RNA, Small Interfering 0
Focal Adhesion Kinase 1 EC 2.7.10.2
PTK2 protein, human EC 2.7.10.2
Doxycycline N12000U13O

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

49-59

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that there is no conflict of interest regarding the publication of this paper.

Auteurs

C Molist (C)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

N Navarro (N)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

I Giralt (I)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

P Zarzosa (P)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

G Gallo-Oller (G)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

G Pons (G)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

A Magdaleno (A)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

L Moreno (L)

Pediatric Oncology and Hematology Department, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

G Guillén (G)

Pediatric Surgery Department, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Spain.

R Hladun (R)

Pediatric Oncology and Hematology Department, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

M Garrido (M)

Pathology Department, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Spain.

A Soriano (A)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

M F Segura (MF)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

J Sánchez de Toledo (J)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Pediatric Oncology and Hematology Department, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

S Gallego (S)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Pediatric Oncology and Hematology Department, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: sgallego@vhebron.net.

J Roma (J)

Laboratory of Translational Research in Child and Adolescent Cancer, Vall D'Hebron Research Institute, Hospital Universitari Vall D'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: josep.roma@vhir.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH